Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.
Publication
, Conference
O'Donnell, PH; Rosenberg, JE; Hoimes, CJ; Petrylak, DP; Milowsky, MI; Mckay, RR; Srinivas, S; Friedlander, TW; Ramamurthy, C; Bilen, MA; Mar, N ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
O’Donnell, P. H., Rosenberg, J. E., Hoimes, C. J., Petrylak, D. P., Milowsky, M. I., Mckay, R. R., … Flaig, T. W. (2023). Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
O’Donnell, Peter H., Jonathan E. Rosenberg, Christopher J. Hoimes, Daniel P. Petrylak, Matthew I. Milowsky, Rana R. Mckay, Sandy Srinivas, et al. “Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
O’Donnell PH, Rosenberg JE, Hoimes CJ, Petrylak DP, Milowsky MI, Mckay RR, et al. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
O’Donnell, Peter H., et al. “Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023.
O’Donnell PH, Rosenberg JE, Hoimes CJ, Petrylak DP, Milowsky MI, Mckay RR, Srinivas S, Friedlander TW, Ramamurthy C, Bilen MA, Burgess EF, Mar N, Moon H, Geynisman DM, George S, Carret A-S, Yu Y, Guseva M, Moreno BH, Flaig TW. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences